Half-Life and Accumulation: Why Effects Strengthen Over Weeks

What accumulation means

When you inject a compound with a half-life longer than your dosing interval, each new dose adds to what remains from the previous dose. Accumulation is the buildup of active concentration over repeated doses until reaching steady state — the point where the amount eliminated between doses equals the amount injected.

This matters practically: a tirzepatide user in week 8 of weekly dosing has significantly higher active concentrations than in week 1. The therapeutic effect, and any side effects, reflect that steady-state level — not the single-dose pharmacology.

Steady state: when accumulation stops

Steady state is reached after approximately 4–5 half-lives of regular dosing. At that point, each new dose replaces exactly what cleared since the last dose, and average concentrations plateau.

The accumulation formula

Active concentration at time t after the n-th dose, assuming consistent dosing:

C(t) = Dose × (1 − 0.5^n) / (1 − 0.5^(interval/t½)) × 0.5^(t/t½)

This simplifies to: at steady state, the average concentration is approximately Dose / (1 − 0.5^(interval/t½)). For tirzepatide at 10 mg weekly with a 5-day half-life:

• After dose 1: peak ~10 mg active.
• After 4 weeks (4 doses): peak ~17–18 mg active (accumulation factor ~1.7–1.8×).
• After ~5 weeks: steady state, peak stabilizes around the same level.

See this curve in the half-life chart — set your compound, dose, and schedule to visualize how active levels change across weeks of dosing.

Why accumulation explains why effects strengthen over weeks

A common question from GLP-1 users: "I'm on week 3 and it finally seems to be working. Why did it take so long?" The pharmacokinetics answer: you hadn't reached steady state yet. At week 1, peak active levels may be 60% of steady state. By week 5, you're at full steady-state exposure and experiencing the drug's full effect at that dose.

This is also why dose-escalation protocols wait 4 weeks between steps: you need to be at steady state to evaluate tolerability and efficacy at the current dose before increasing.

Accumulation and clearance after stopping

Clearance after the last dose takes the same 4–5 half-life window. For tirzepatide (5-day half-life), stopping after reaching steady state means:

• After 1 week: ~50% remaining.
• After 2 weeks (14 days): ~25% remaining.
• After 3–4 weeks: <10% remaining.
• After 5 weeks: <5% remaining (effectively cleared).

For semaglutide (7-day half-life), the same thresholds take proportionally longer. This clearance window matters for surgical planning, starting other medications with interactions, or understanding when appetite suppression fades.

Compounds with no meaningful accumulation

BPC-157 (4-hour half-life, once-daily dosing) clears almost entirely between doses — roughly 97% cleared in 20 hours. There is no clinically significant accumulation. Each dose is effectively a fresh start.

CJC-1295 (no DAC, 30-minute half-life, once-daily) is even more extreme — it clears within 2–3 hours. The therapeutic window is the first hour post-injection, which is why timing relative to meals matters so much.

Understanding whether a compound accumulates helps you understand why some compounds feel "on or off" (short half-life, no accumulation) while others feel like they're building over weeks (long half-life, accumulation to steady state).

Multi-compound accumulation: why a chart helps

Running BPC-157 (no accumulation, daily), TB-500 (loading phase accumulation, twice weekly), and tirzepatide (steady-state accumulation, weekly) simultaneously means you're dealing with three completely different pharmacokinetic profiles at once. A spreadsheet or notes app won't show you the combined active concentration picture.

The My Pep Calc half-life chart renders all active compounds in your protocol on one timeline, so you can see the BPC-157 daily pulses alongside TB-500's loading accumulation curve and tirzepatide's slow rise to steady state — all from your actual logged doses.